Pliant Therapeutics, Inc. (PLRX)
| Market Cap | 71.20M -26.0% |
| Revenue (ttm) | n/a |
| Net Income | -113.22M |
| EPS | -1.84 |
| Shares Out | 61.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 439,110 |
| Open | 1.160 |
| Previous Close | 1.165 |
| Day's Range | 1.130 - 1.170 |
| 52-Week Range | 1.090 - 1.950 |
| Beta | 1.21 |
| Analysts | Hold |
| Price Target | 2.67 (+132.17%) |
| Earnings Date | May 11, 2026 |
About PLRX
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price target is $2.67, which is an increase of 132.17% from the latest price.
News
Pliant Therapeutics reports Q1 EPS (32c), consensus (36c)
“In the first quarter, our team showcased its clinical development capabilities, initiating FORTIFY, the Phase 1b trial of PLN-101095, ahead of schedule and dosing the first patient in April,” said…
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confi...
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-base...
Pliant Therapeutics doses first participant in FORTIFY expansion trial
Pliant Therapeutics (PLRX) announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in pati...
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication exp...
Pliant announces presentation of updated data from Phase 1 trial of PLN-101095
Pliant Therapeutics (PLRX) announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor-refractory a...
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months
Pliant Therapeutics files $300M mixed securities shelf
18:00 EDT Pliant Therapeutics (PLRX) files $300M mixed securities shelf
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-ba...
Pliant Therapeutics price target lowered to $3 from $4 at Canaccord
Canaccord lowered the firm’s price target on Pliant Therapeutics (PLRX) to $3 from $4 and keeps a Hold rating on the shares. The firm said Pliant reported financial results and…
Pliant Therapeutics price target lowered to $3 from $4 at Piper Sandler
Piper Sandler lowered the firm’s price target on Pliant Therapeutics (PLRX) to $3 from $4 and keeps an Overweight rating on the shares. At Q4/FY25 earnings, Pliant provided a thoughtful…
Pliant Therapeutics reports Q4 EPS (38c), consensus (38c)
“We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated development plan for…
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indicatio...
Pliant Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Transitioned focus to oncology with lead integrin-targeting program PLN-101095, showing promising phase I results and a strong safety profile. Phase Ib study starts in Q2, with a robust cash position supporting aggressive development and ongoing evaluation of new pipeline and partnering opportunities.
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-bas...
Pliant Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Durable responses and a favorable safety profile were observed in the phase 1 study, prompting advancement to a phase 1b trial in non-small cell lung cancer and other tumors. The pipeline will expand with new programs by 2026, supported by a strong cash position through 2028.
Pliant Therapeutics announces interim data from PLN-101095
Pliant Therapeutics (PLRX) announced interim data from its Phase 1 dose escalation clinical trial evaluating PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor...
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatmen...
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based thera...
Pliant Therapeutics reports Q3 EPS (43c), consensus (52c)
“During the third quarter, our team continued to advance our portfolio while winding down activities surrounding the BEACON-IPF trial,” said Bernard Coulie, President and Chief Executive Officer of Pl...
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NE...
Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Pliant Therapeutics (PLRX) to Underweight from Neutral without a price target The firm says the investment story “has remained in limbo” since the bexotegrast program for idiopathi...
Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi
Citi analyst David Lebowitz raised the firm’s price target on Pliant Therapeutics (PLRX) to $1.70 from $1.50 and keeps a Neutral rating on the shares post the Q2 report. The…
Pliant Therapeutics price target lowered to $4 from $17 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $4 from $17 and keeps an Overweight rating on the shares. The firm cites cash…
Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)
Reports Q2 cash, cash equivalents and short-term investments of $264.4M. The company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis. “While our activities in the quarter ...